Cliff Asness's PTCT Position Overview
Cliff Asness (via Aqr Capital Management LLC) currently holds 331,256 shares of PTC Therapeutics, Inc. (PTCT) worth $20.33 M, representing 0.01% of the portfolio. First purchased in 2014-Q3, this long-term strategic position has been held for 45 quarters.
Based on 13F filings since 2013, Cliff Asness has maintained a long-term strategic position in PTCT, representing a significant commitment to this investment thesis. Largest addition occurred in Q1 2025, adding 255,674 shares. Largest reduction occurred in Q3 2025, reducing 205,860 shares.
Analysis based on 13F filings available since 2013 Q2
Cliff Asness's PTC Therapeutics (PTCT) Holding Value Over Time
Track share changes against reported price movement
Quarterly PTC Therapeutics (PTCT) Trades by Cliff Asness
| Period | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q3 2014 | +42,700 | New Buy | 42,700 | $44.00 |
| Q4 2014 | +9,676 | Add 22.66% | 52,376 | $51.78 |
| Q1 2015 | +29,900 | Add 57.09% | 82,276 | $60.84 |
| Q2 2015 | +13,447 | Add 16.34% | 95,723 | $48.13 |
| Q3 2015 | -47,900 | Reduce 50.04% | 47,823 | $26.70 |
| Q4 2015 | -47,823 | Sold Out | 47,823 | $0.00 |
| Q1 2016 | +85,397 | New Buy | 85,397 | $6.44 |
| Q2 2016 | -85,397 | Sold Out | 85,397 | $0.00 |
| Q1 2017 | +12,224 | New Buy | 12,224 | $9.82 |
| Q2 2017 | +38,330 | Add 313.56% | 50,554 | $18.34 |
| Q3 2017 | +23,060 | Add 45.61% | 73,614 | $20.01 |
| Q4 2017 | -50,289 | Reduce 68.31% | 23,325 | $16.68 |
| Q1 2018 | -5,747 | Reduce 24.64% | 17,578 | $27.08 |
| Q2 2018 | +27,526 | Add 156.59% | 45,104 | $33.72 |
| Q3 2018 | +66,154 | Add 146.67% | 111,258 | $47.00 |
| Q4 2018 | +141,602 | Add 127.27% | 252,860 | $34.32 |
| Q1 2019 | -10,232 | Reduce 4.05% | 242,628 | $37.64 |
| Q2 2019 | -182,015 | Reduce 75.02% | 60,613 | $45.01 |
| Q3 2019 | -25,584 | Reduce 42.21% | 35,029 | $33.83 |
| Q4 2019 | +54,175 | Add 154.66% | 89,204 | $48.02 |
| Q1 2020 | -2,546 | Reduce 2.85% | 86,658 | $44.61 |
| Q2 2020 | -8,976 | Reduce 10.36% | 77,682 | $50.75 |
| Q3 2020 | -49,898 | Reduce 64.23% | 27,784 | $46.75 |
| Q4 2020 | -17,029 | Reduce 61.29% | 10,755 | $60.99 |
| Q1 2021 | -6,172 | Reduce 57.39% | 4,583 | $47.35 |
| Q2 2021 | -4,583 | Sold Out | 4,583 | $0.00 |
| Q4 2021 | +5,227 | New Buy | 5,227 | $39.79 |
| Q1 2022 | +30,748 | Add 588.25% | 35,975 | $37.30 |
| Q2 2022 | -23,960 | Reduce 66.60% | 12,015 | $40.03 |
| Q3 2022 | +904 | Add 7.52% | 12,919 | $50.24 |
| Q4 2022 | +49,475 | Add 382.96% | 62,394 | $38.17 |
| Q1 2023 | +4,565 | Add 7.32% | 66,959 | $48.44 |
| Q2 2023 | +5,611 | Add 8.38% | 72,570 | $40.67 |
| Q3 2023 | +37,831 | Add 52.13% | 110,401 | $22.41 |
| Q4 2023 | -81,578 | Reduce 73.89% | 28,823 | $27.56 |
| Q1 2024 | -11,930 | Reduce 41.39% | 16,893 | $29.09 |
| Q2 2024 | +52,019 | Add 307.93% | 68,912 | $30.58 |
| Q3 2024 | +120,667 | Add 175.10% | 189,579 | $37.10 |
| Q4 2024 | -32,230 | Reduce 17.00% | 157,349 | $45.14 |
| Q1 2025 | +255,674 | Add 162.49% | 413,023 | $50.96 |
| Q2 2025 | +124,093 | Add 30.05% | 537,116 | $48.84 |
| Q3 2025 | -205,860 | Reduce 38.33% | 331,256 | $61.37 |
Cliff Asness's PTC Therapeutics Investment FAQs
Cliff Asness first purchased PTC Therapeutics, Inc. (PTCT) in Q3 2014, acquiring 42,700 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness has held PTC Therapeutics, Inc. (PTCT) for 45 quarters since Q3 2014. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness's largest addition to PTC Therapeutics, Inc. (PTCT) was in Q1 2025, adding 413,023 shares worth $21.05 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
According to the latest 13F filing for Q3 2025, Cliff Asness's firm, Aqr Capital Management LLC, owns 331,256 shares of PTC Therapeutics, Inc. (PTCT), valued at approximately $20.33 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
As of the Q3 2025 filing, PTC Therapeutics, Inc. (PTCT) represents approximately 0.01% of Cliff Asness's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness's peak holding in PTC Therapeutics, Inc. (PTCT) was 537,116 shares, as reported at the end of Q2 2025. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.